title: Syndrome of inappropriate antidiuretic hormone secretion associated with primary cutaneous anaplastic large cell lymphoma.
authors.affiliation: Department of Internal Medicine, Osaka Medical College, Takatsuki City, Osaka, Japan.
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hirata
authors.forename: Taiji
authors.initials: T
authors.lastname: Yokote
authors.forename: Uta
authors.initials: U
authors.lastname: Nishiwaki
authors.forename: Motomu
authors.initials: M
authors.lastname: Tsuji
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hanafusa
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000150:complications* / Q000175:diagnosis* / Q000628:therapy; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D009367:Neoplasm Staging; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D012965:Sodium Chloride; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone